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ABSTRACT
Objective: To review the efﬁcacy of instrumental variable (IV) models in
addressing a variety of assumption violations to ensure standard ordinary
least squares (OLS) estimates are consistent. IV models gained popularity
in outcomes research because of their ability to consistently estimate the
average causal effects even in the presence of unmeasured confounding.
However, in order for this consistent estimation to be achieved, several
conditions must hold. In this article, we provide an overview of the IV
approach, examine possible tests to check the prerequisite conditions, and
illustrate how weak instruments may produce inconsistent and inefﬁcient
results.
Methods: We use two IVs and apply Shea’s partial R-square method, the
Anderson canonical correlation, and Cragg–Donald tests to check for
weak instruments. Hall–Peixe tests are applied to see if any of these
instruments are redundant in the analysis.
Results: A total of 14,952 asthma patients from the MarketScan Com-
mercial Claims and Encounters Database were examined in this study.
Patient health care was provided under a variety of fee-for-service, fully
capitated, and partially capitated health plans, including preferred pro-
vider organizations, point of service plans, indemnity plans, and health
maintenance organizations. We used controller–reliever copay ratio and
physician practice/prescribing patterns as an instrument. We demonstrated
that the former was a weak and redundant instrument producing incon-
sistent and inefﬁcient estimates of the effect of treatment. The results were
worse than the results from standard regression analysis.
Conclusion: Despite the obvious beneﬁt of IV models, the method should
not be used blindly. Several strong conditions are required for these models
to work, and each of them should be tested. Otherwise, bias and precision
of the results will be statistically worse than the results achieved by simply
using standard OLS.
Keywords: asthma, instrumental variable, propensity score, regression
analysis.
Introduction
Causal inference is challenging in all nonexperimental studies
because of the possibility of overt and hidden bias [1]. When
evaluating certain treatment programs, overt bias can exist
because the treatment and control groups are different in terms of
certain observable factors, such as age, gender, and comorbidi-
ties. Hidden bias may exist as a result of failure to control for
unobservable factors, such as doctors’ practice/prescription pat-
terns [2]. Practice patterns might be based on physician rules of
thumb, experiences and interactions with patients and colleagues
as well as comprehensive empirical evidence. Prescription pat-
terns are inﬂuenced by nonclinical factors. For example, health
plans provide different ﬁnancial and nonﬁnancial incentives to
doctors or patients to undergo aggressive treatment [3]. It is not
feasible to measure all of these characteristics in observational
data.
Propensity score matching and regression analysis are two
statistical techniques used to remove overt bias. Although regres-
sion analysis is widely used in applied economics literature, pro-
pensity score methods are increasingly used in medical literature.
A systematic literary search by Stürmer et al. found that the
annual number of publications using propensity score methods
increased from 8 to 71 from 1998 to 2003 [4]. Last year, the
number of propensity score methods used was 171.
Baser describes the conditions outlining which method is
optimal for controlling for observable bias [2]. Although effec-
tively controlling for observable bias, neither propensity score
matching nor regression adjustment addresses problems because
of imbalances in unmeasured factors. For this reason, interest in
instrumental variable (IV) approach is growing.
Notions of causality in econometrics and their relationship
with IVs and other methods are discussed in Heckman [5].
Econometric literature on notions of causality goes back to early
work by Ashenfelter [6] and subsequent work by Ashenfelter and
Card [7], Heckman and Robb [8], Lalonde [9], Fraker and
Maynard [10], Card and Sullivan [11] and Manski [12,13]. The
use of IV technique in outcomes research has increased in recent
years because even in the presence of hidden bias, such methods
may consistently estimate the average causal effects [14]. We are
in the beginning stage of this application on outcomes research
studies and believe the surge is yet to start [15–19].
However, like many techniques borrowed from one discipline
and applied to another, there is a tendency to apply this method
blindly. Researchers, unaware of the shortcomings of this tech-
nique, may apply it inappropriately. In this article, we draw
attention to the problem of using instruments that explain little
of the variation in the endogenous explanatory variables (such as
treatment choice variables, etc.). These instruments can lead to
large inconsistencies in IV estimates. The magnitude of the bias
of IV estimates approaches that of ordinary least squares (OLS)
estimates as the R-square between the instruments and the
endogenous variable approaches zero. While these results are
known in economics literature, their potential implications for
empirical work related to outcomes research have not been fully
appreciated.
The discussion in this article does not provide detailed or
rigorous treatment of the theory that premises the IV approach.
In recent years, several books on IV methods, with various levels
of sophistication, have been published. Wooldridge’s book is an
excellent source for researchers with an elementary level of
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statistical knowledge [20]. His more advanced book provides
detailed information on IV for readers with an advanced math-
ematical background [21]. The work of Bowden and Turkington
is geared toward mathematical outcomes researchers [22].
Curious readers are encouraged to consult these books for a
more detailed analysis.
Overview of IV Estimation
Suppose we want to estimate the effect of treatment (T) on
outcome (Y), i.e., estimate b1 in:
Y T e= + +β β0 1
For simplicity, we assume dichotomous treatment variable (T),
homogeneous treatment effect, linear regression, and no covari-
ates. e is unobservable. Least squares estimate of the equation
yields the following estimator:
β1 1 0OLS T TY Y= −= = ,
which is the difference in mean outcomes. In order to reach a
consistent estimator, the key assumption is that treatment (T) is
not correlated with the unobserved determinants of the outcome
(e).
E T T Y T T T T YOLS OLS′( ) = ⇒ ′ − ′( ) = ⇒ = ′( ) ′−ε β β0 0 1ˆ ˆ
The OLS assumption is unlikely to hold, because treatment is
related to omitted factors inﬂuencing outcome. For example,
patients who are more severely ill in ways known to their phy-
sicians but not to the analyst might not get the treatment, or vice
versa.
In order to obtain a consistent estimator of b0 and b1 when
treatment and omitted factors are related, we need additional
information.
The information comes by way of a new variable—an
IV—(Z) that satisﬁes the following properties:
1. Cov(Z,e) = 0 Z should have no partial effect on the out-
comes variable and should not be correlated with other
factors that affect the outcomes variable.
2. Cov(Z,T)  0 Z must be related, either positively or nega-
tively, to the treatment indicator.
If these two conditions are satisﬁed, then the IV estimator is:
E Z e Z Y T Z T Z YIV IV′( ) = ⇒ ′ −( ) = ⇒ = ′( ) ′−0 0 1ˆ ˆβ β
Note that all IV results apply asymptotically. Small sample esti-
mation properties of IV are more complex and, as discussed in
the next section, not generally understood. Variants on this
approach include two-stage least squares [21,23,24], limited
information maximum likelihood estimator [21,25], general
method of moments [21,26], and sample selection corrections
(“Heckit”) [21,27].
The coin toss in the context of randomized controlled trials
(RCTs) is a perfect example of IV. The coin toss does not effect
the outcome of interest directly (assumption (i)) but it determines
treatment assignment (assumption (ii)). Following are some
examples of IVs that have been used in applied research:
1. Geography (distance, rivers, small area variation) [28–32].
2. Legal/political institutions (laws, election dynamics)
[31,33,34].
3. Administrative rules (wage/stafﬁng rules, reimbursement
rules, eligibility rules) [35–37].
4. Naturally occurring randomization (blood type of recipi-
ents, draft, birth timing, lottery, roommate assignment)
[36,38–40].
Why Not Always Use IV?
The immediate question that arises is if the IV method is superior
to risk adjustment methods such as propensity score matching or
multivariate regression in the sense that these methods both
cover observable and unobservable factors, why not always use
the IV method?
First, it is hard to ﬁnd variables that meet the deﬁnition of
valid instruments. Conceptually, most variables that have an
effect on treatment variables may also have a direct effect on the
outcomes variable.
Second, the standard errors of IV estimates are likely to be
larger than those of OLS estimates, creating publication bias. It is
important to understand that publication bias may exist even
without the authors of individual studies being aware of it. The
potential problem simply arises because of the desire to report
signiﬁcant ﬁndings. Although lack of treatment is useful to
report, evidence against the null hypothesis—that is, favorable to
the ﬁnding of a treatment effect—is more likely to be reported.
Because IV estimates have to be larger in order to be signiﬁcant,
published results tend to create publication bias [41].
Third, the desirable properties of the IV estimator hold in
large sample sizes. With simulation, Grootendorst showed that in
small sample sizes, the estimates can be highly inaccurate [17].
Also, refer to Kinal for related issues with small properties, where
the IV estimator may have no expected value [42].
Fourth, the interpretation of IV is difﬁcult, especially when
the treatment effect is heterogeneous. Randomized clinical trials
estimate the treatment effect in well-deﬁned populations. There-
fore, there are always issues of external validity. Analogous issues
arise with IV estimates. They estimate treatment effect for the
“marginal” patients whose treatment is affected by the instru-
ments. Therefore, they often do not estimate treatment effect in
the general population [43].
The last sets of problems are related to weak instruments,
which are the focus of this article.
Weak Instruments
There is a very important difference between the two require-
ments for an IV. Because assumption (i) is a covariance between
the IVs and the unobservable error u, it can never be directly
checked or even tested. Rather, we must maintain this assump-
tion by appealing to clinical behavior (in the presence of multiple
instruments, indirect tests can be conducted. See Wooldridge for
details [21]).
By contrast, assumption (ii) that IV is correlated with treat-
ment choice can be tested, given a random sample from the
population. If this correlation is weak, this may lead to large
inconsistencies in IV estimates with the bias in the same direction
as that of OLS estimates [44]. Because IV estimates also have
larger standard errors than those of OLS estimates, as pointed
out by Bound et al., “. . . the cure can be worse than the disease”
[45].
Testing forWeak Instruments
Staiger and Stock formalized the deﬁnition of weak instruments
and most researchers appear to have concluded (incorrectly)
from that work that if F-statistics on coefﬁcients of exogenous
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variables on the endogenous treatment indicator is greater than
10, one need to worry no further about weak instruments [43].
Another statistic commonly used, as recommended by Bound
et al., is the R2 of the regression with instruments partialed out
[45]. However, Shea showed, in general, the distribution of this
F-statistic is nonstandard [46]. Also, for models with multiple
endogenous variables, these indicators may not be sufﬁciently
informative [46].
To grasp the pitfalls facing empirical researchers here, con-
sider the following simple example. We have a model with two
endogenous covariates (treatment and insurance choice) and two
instruments (distance to nearest specialized hospital and small
area variation). Distance to nearest specialized hospital increases
the likelihood of being admitted in a specialized hospital. There-
fore, patients near a specialized hospital are more likely to be
treated by specialized medical staff, in a special care unit, and
with other dimensions of higher intensity. Distance to nearest
specialized hospital might also affect the insurance choice. The
differences between each managed care plan lie mainly in the
degree of compensation one receives for medical treatment
outside the managed care network. Patients who live close to a
specialized hospital are more likely to choose a low premium
insurance plan.
Small area variations in hospital surgical volumes might affect
the treatment quality. Because volume is positively correlated
with surgical quality, patients who live in high volume areas
might get better treatment choices than patients who live in low
volume areas. Therefore, both distance to nearest specialized
hospital and small area variation in hospital volumes are valid
instruments because they have a direct effect on treatment or
insurance choice but indirectly related to the outcome.
Suppose the distance to the nearest specialized hospital is
highly correlated with treatment and insurance choice, but the
small area variation is just a noise. In this case, because we have
one instrument for two endogenous variables, this model is unde-
ridentiﬁed. Bound et al.’s F-statistics [45] and partial R-squared
measures from regression with instruments will not reveal this
weakness. Indeed, the F-statistics are statistically signiﬁcant and
without investigation, but we may not realize the model cannot
be estimated in this form. The statistics proposed by Bound et al.
[45] diagnose instruments relevant only in the presence of one
endogenous covariate.
When multiple endogenous variables are used, other statistics
can be used. Shea provided such statistics [46]. Shea’s R-squares
take the intercorrelations among instruments into account. As a
rule of thumb, if an estimated equation yields a large value of the
standard partial R-squares and a small value of the Shea
measure, we should conclude that the instruments lack sufﬁcient
relevance to explain all the endogenous regressors.
A more general approach to weak instruments was proposed
by Anderson [47] and discussed in Hall and Peixe [48]. Ander-
son’s approach considers the canonical correlations of the
excluded and included instruments. This test shows whether
some instruments are redundant. Stock and Yogo go into more
details and provide useful rules of thumb regarding the weakness
of instruments based on a statistic from Cragg and Donald
[49,50].
Data Sources and Construction of Variables
We illustrate the implications of a weak IV using MarketScan
data to examine the effect of controller medication on health-care
expenditures for asthma patients. Brieﬂy, the MarketScan Com-
mercial Claims and Encounters Database contains detailed
descriptions of inpatient, outpatient, medical, and outpatient
prescription drug services for approximately 13 million persons
in 2005 who were covered by corporate-sponsored health-care
plans.
Details of the patient selection criteria are provided in Crown
et al. [51] and summarized as follows:
1. Patients with evidence of asthma were selected from the
intersection of the medical claims and encounter records,
enrollment ﬁles, and pharmaceutical data ﬁles.
2. Individuals meeting at least one of the following criteria
were deemed to show evidence of asthma:
• At least two outpatient claims with primary or second-
ary diagnoses of asthma.
• At least one emergency room (ER) claim with primary
diagnosis of asthma, and a drug transaction for an
asthma medication 90 days before or 7 days after the
ER claim.
• At least one inpatient claim with a primary diagnosis
of asthma.
• A secondary diagnosis of asthma and a primary diag-
nosis of respiratory infection in an outpatient or inpa-
tient claim.
• At least one drug transaction for an anti-inﬂammatory
agent, oral antileukotrienes, long-acting bronchodila-
tor, or inhaled or oral short-acting beta-agonists.
3. Patients with a diagnosis of chronic obstructive pulmonary
disease and having one or more diagnoses or procedure
codes indicating pregnancy or delivery, or who were not
continuously enrolled for 24 months, were excluded from
our study group.
The sociodemographic characteristics include age of the
household, percentage of the patients who were female, and
geographic region (northeast, north-central, south, west, and
“other” region). Charlson comorbidity index scores are gener-
ated to capture the level and burden of comorbidity. Point-of-
service plans and other plan types, including health maintenance
organizations and preferred provider organizations, are included.
The analytic ﬁle contains patients with fee-for-service (FFS)
health plans and those with partially or fully capitated plans.
Data on costs are not available for the capitated plans however.
Therefore, the value of patients’ service utilization under the
capitated plans is priced and imputed using average payments
from the MarketScan FFS inpatient and outpatient services by
region, year, and procedure.
The outcomes variable is total health-care costs. The
MarketScan database contains information on all payments
processed with regard to reimbursement for particular services,
including secondary payers and patient out-of-pocket costs. For
services in which these MarketScan employers are a secondary
payer (i.e., the patient has other primary insurance), the amounts
paid by other insurers is also documented and included in the
cost. In cases where services delivered are completely covered by
another primary insurance, these claims are not included in the
database. Data on costs were not available for the capitated
plans. Therefore, the value of patients’ service utilization under
the capitated plan was priced and imputed using average pay-
ments from the MarketScan FFS inpatient and outpatient services
by region, year, and procedure.
The endogenous variable is treatment choice (= 1 if controller,
= 0 if reliever). Asthma drugs can be reliever medications (used to
relieve symptoms in an acute asthmatic exacerbation or asthma
attack) or primarily controller medications (used to control pul-
monary inﬂammation and prevent an attack).
The IVs are controller/reliever copay ratio and physician/
practice prescribing pattern. Copayments for outpatient pharma-
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ceuticals are calculated by ﬁrst stratifying all prescription drug
claims by year, then by plan within year. We then calculate the
average out-of-pocket patient copayments for asthma drugs by
therapeutic class for each plan to calculate the ratio of mean
controller payments to mean reliever copayments. These plan-
level ratios are attached to each patient’s record for a given plan.
Our second IV involves calculation of the proportion of patients
obtaining controller medication for each physician/provider tax
identiﬁcation number. In many cases, this tax identiﬁcation
number includes a multiphysician medical practice, but in some
cases is unique to one physician.
Results
The objective of this study was to estimate the cost of illness for
asthma patients treated with controller and reliever medications
using the IV approach.
Table 1 reports the demographic characteristics of the
sample, stratiﬁed by treatment choice. Patients using controller
medication had a mean age of 40 years (compared with 30 years
for patients using reliever medication) and were more likely to be
female. The racial distribution in counties was similar between
the two groups. Patients treated with controller medication were
more likely to receive their health-care coverage as an employee
compared with those with reliever medication. Signiﬁcant differ-
ences in mean income between the two groups were evident from
county-level US census data compared with the claims data.
Patients treated with controller medication had higher numbers
of major diagnostic categories, higher Charlson comorbidity
scores, and higher rates of asthma speciﬁc comorbidities. The
descriptive table shows that the ratio of mean controller copay-
ments to mean reliever copayments was lower for the treated
controller group relative to the reliever group. Physicians were
more likely to prescribe controller medication to the patient
group treated with controller medication. The unadjusted total
health-care costs were signiﬁcantly higher for patients treated
with controller medication relative to the ones who were treated
with reliever medication.
Because the Hausman test showed the treatment choice is
endogenous, the IV method has been applied [52]. (P < 0.000)
We have two possible candidates for instrument: controller/
reliever copay ratio and physician/practice prescribing pattern.
The ﬁrst key assumption for IV is that it does not independently
affect the outcome, so it is not associated with measured and
unmeasured health status. Table 2 shows a different division of
the sample from Table 1, namely division according to quintile
of IVs. The ﬁrst assumption, that copay ratios and prescribing
patterns affect health-care costs only through its effect on the
Table 1 Summary of asthma patient characteristics
Variables
Controller medication
(n = 3,903)
Reliever medication
(n = 11,049)
P-values
STD
differenceMean STD Mean STD
Explanatory Variables
Age 39.74 16.52 30.50 18.07 0.0000 53.38
(%) Female 0.63 0.48 0.57 0.49 0.0000 11.87
Race
White 0.84 0.14 0.85 0.13 0.2737 5.49
Black 0.09 0.11 0.09 0.10 0.3819 4.41
Other 0.02 0.02 0.02 0.02 0.7958 3.47
Geographic Regions
Northeast 0.02 0.15 0.02 0.13 0.1442 2.66
North-Central 0.81 0.39 0.85 0.36 0.0000 10.86
South 0.02 0.15 0.02 0.13 0.1442 2.66
West 0.04 0.20 0.04 0.19 0.4918 1.27
Year of Patient Identiﬁcation
1996 0.40 0.49 0.39 0.49 0.3035 1.91
1997 0.26 0.44 0.28 0.45 0.0142 4.59
1998 0.31 0.46 0.31 0.46 0.5362 1.15
1999 0.02 0.15 0.02 0.13 0.0209 4.15
Member Type
Employee 0.49 0.50 0.35 0.48 0.0000 29.54
Spouse 0.27 0.45 0.20 0.40 0.0000 18.72
Dependents
4–11 Years 0.08 0.27 0.19 0.39 0.0000 32.31
12–18 Years 0.11 0.32 0.21 0.41 0.0000 25.59
Others 0.04 0.20 0.06 0.24 0.0000 9.99
County Mean Household Income $25,829 $6,686 $24,997 $6,141 0.0000 12.95
Number of Major Diagnosis Categories 6.80 2.39 6.06 2.15 0.0000 32.58
Charlson Comorbidity Index 0.92 1.18 0.49 0.92 0.0000 40.73
Asthma-Speciﬁc Comorbidities
Allergic Rhinitis 0.28 0.45 0.18 0.39 0.0000 23.94
Migraine 0.07 0.26 0.05 0.22 0.0000 8.43
Depression 0.10 0.30 0.10 0.30 0.3604 1.69
Gastrointestinal Disorder 0.28 0.45 0.21 0.41 0.0000 16.44
Sinusitis 0.27 0.44 0.23 0.42 0.0000 7.81
Anxiety 0.03 0.16 0.02 0.15 0.4556 1.38
Instrumental Variables
Controller/Reliever Copayment 1.32 0.30 1.29 0.26 0.0000 14.08
Tax Provider ID Controller % 0.61 0.05 0.60 0.04 0.3144 20.73
Tax Provider ID Reliever % 0.39 0.05 0.40 0.04 0.3144 20.73
Outcomes Variable
Total Cost $4,321 $7,011 $2,792 $6,151 0.0000 23.18
ID, identiﬁcation number; STD, standard deviation.
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likelihood of treatment choice, cannot be tested directly. We can,
however, indirectly test this assumption and see how realistic it is
a priori. This assumption would be satisﬁed if a person’s copay
ratio or physician practice/prescribing pattern was not associated
with the clinical severity of the asthma, the primary unobserved
variable that will determine the treatment. If this is true, IVs
should also be independent of observed variables such as age,
gender, and comorbidities, associated with health status and
hence the likelihood of treatment choice. The data in Table 2
show that observable factors are independent across the
quintiles.
We also tested whether these instruments satisﬁed the second
assumption: are they highly correlated with treatment?
By looking at the quintiles in Table 2, we can see the corre-
lation between treatment choice and the IVs across the quintiles.
Among the physicians who are most likely to give prescriptions
for controllers, the number of patients who are getting controller
medication is almost two times higher. However, the likelihood
of being prescribed controller medications was similar across the
quintiles of copay ratios.
First, we used only controller/reliever copay ratio as an IV
(see Table 3). Shea’s partial R-square was very small for this
equation. The Cragg–Donald statistic failed to reject its null
hypothesis of underidentiﬁcation. The Anderson canonical cor-
relation failed to reject its null hypothesis at the 10% level,
suggesting that the instrument may be inadequate to identify the
equation. Second, we used only physician/practice prescribing
patterns as an IV. Shea’s partial R-square was 0.58 for this
equation. The Cragg–Donald statistic rejected its null hypothesis
of underidentiﬁcation. The Anderson canonical correlation
rejected its null hypothesis, suggesting that the instrument was
adequate to identify the equation. We also attempted both instru-
ments at the same time, but the Hall–Peixe test showed that ratio
of copays as an instrument was redundant. The Hausman–Taylor
Table 2 Descriptive statistics on asthma patients by quintiles of instrumental variables
Variables
IV-1: controller/reliever ratio IV-2: controller/reliever ratio
Q1 Q2 Q3 Q4 Q5 Q1 Q2 Q3 Q4 Q5
Explanatory Variables
Age 31.62 31.81 30.52 30.93 40.22 31.20 31.49 26.59 31.55 41.61
(%) Female 0.59 0.61 0.56 0.56 0.62 0.57 0.59 0.52 0.59 0.62
Race
White 0.88 0.87 0.86 0.79 0.78 0.87 0.86 0.75 0.85 0.79
Black 0.08 0.07 0.08 0.08 0.13 0.08 0.08 0.11 0.07 0.12
Other 0.02 0.02 0.02 0.03 0.03 0.02 0.02 0.04 0.02 0.03
Geographic Regions
Northeast 0.00 0.00 0.02 0.02 0.06 0.00 0.00 0.21 0.00 0.04
North-Central 1.00 0.95 0.92 0.61 0.54 0.99 0.91 0.28 0.86 0.59
South 0.00 0.00 0.02 0.02 0.06 0.00 0.00 0.21 0.00 0.04
West 0.00 0.02 0.02 0.17 0.07 0.00 0.00 0.17 0.07 0.09
Year of Patient Identiﬁcation
1996 0.08 0.00 0.87 0.39 0.37 0.93 0.09 0.02 0.00 0.29
1997 0.85 0.00 0.04 0.04 0.38 0.07 0.86 0.87 0.00 0.17
1998 0.07 0.93 0.09 0.56 0.24 0.00 0.06 0.10 1.00 0.44
1999 0.00 0.07 0.01 0.01 0.01 0.00 0.00 0.01 0.00 0.10
Member Type
Employee 0.40 0.40 0.37 0.36 0.40 0.35 0.40 0.33 0.40 0.43
Spouse 0.19 0.20 0.18 0.24 0.31 0.20 0.19 0.18 0.20 0.31
Dependents
4–11 Years 0.16 0.14 0.17 0.21 0.14 0.16 0.17 0.27 0.16 0.12
12–18 Years 0.19 0.19 0.22 0.16 0.12 0.22 0.18 0.19 0.17 0.12
Others 0.07 0.07 0.06 0.03 0.03 0.07 0.06 0.02 0.06 0.02
County Mean Household Income $24,691 $26,040 $24,584 $27,610 $24,897 $24,127 $24,640 $26,216 $26,631 $26,069
Number of Major Diagnosis Categories 6.27 6.31 6.30 5.72 6.34 6.30 6.27 5.64 6.18 6.38
Charlson Comorbidity Index 0.54 0.57 0.57 0.55 0.80 0.57 0.56 0.56 0.56 0.80
Asthma-Speciﬁc Comorbidities
Allergic Rhinitis 0.20 0.21 0.21 0.26 0.19 0.21 0.21 0.21 0.22 0.19
Migraine 0.06 0.06 0.05 0.06 0.05 0.06 0.06 0.05 0.06 0.05
Depression 0.11 0.11 0.10 0.10 0.07 0.11 0.11 0.08 0.11 0.07
Gastrointestinal Disorder 0.22 0.23 0.22 0.21 0.28 0.22 0.22 0.23 0.23 0.28
Sinusitis 0.24 0.24 0.25 0.23 0.23 0.25 0.24 0.24 0.24 0.22
Anxiety 0.02 0.03 0.03 0.02 0.02 0.03 0.02 0.03 0.02 0.02
Treatment
Controller Medication 0.22 0.24 0.25 0.26 0.34 0.25 0.23 0.26 0.25 0.34
Outcomes Variable
Total Cost $3,043 $3,223 $2,805 $2,806 $4,134 $2,940 $3,064 $3,150 $3,110 $3,973
IV, instrumental variable.
Table 3 Testing the strength of the instruments
Instruments Shea’s R2 Partial R2 F-stat P-value Cragg–Donald (P-value) Anderson’s test (P-value)
IV-1 0.0023 0.0023 1.78 0.1563 2.79 (0.145) 2.57 (0.165)
IV-2 0.58 0.58 18.65 0 28.54 (0.000) 28.57 (0.000)
IV, instrumental variable.
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test showed the rejection of controller–reliever copay ratio as an
adequate instrument [53].
Our estimation method has two stages. We ﬁrst estimated the
likelihood of prescribing controller medication as a function of
the exogenous covariates and IVs via conventional probit analy-
sis. The results are presented in Table 4. For the second stage
outcome (health-care expenditures) regression, following the
Park test as described by Manning and Mullahy, we chose gen-
eralized linear models (GLMs) with log links and gamma family
[54]. We regressed the total expenditure on treatment choice,
exogenous covariates, and the ﬁrst-stage probit residual as
explanatory variables [55]. The results are presented in Table 5.
In the outcomes tables (Table 6), we compared raw outcomes
between the patient groups that used controller medication only
and reliever medication only, then we used the standard regres-
sion technique to adjust the raw outcome differences for ob-
servable differences in demographic and comorbid diseases
characteristics between these two groups. These estimates were
then compared with three IV estimators: one with weak IV, one
with strong IV, and one with using both of them as an IV (one
being a redundant IV).
The predicted cost differences were similar between standard
regression and IV regression with weak instruments ($260 vs.
$270). However, standard errors of the IV estimator increased
almost 10-fold. Therefore, the differences were insigniﬁcant
according to IV estimation with a weak instrument. However,
using the right IV, with a strong relationship between treatment
variables, there was a signiﬁcant relationship between the health-
care cost of the controller-only user group and reliever-only user
group ($894, P = 0.000). Because the coefﬁcient on treatment
choice in standard GLM regression is positive, downward bias
can explain the positive relationship between the unobserved
severity level and reliever medication use.
Discussion
A widely recognized problem in observational research is that
because of unobservable differences between individuals, it is
unclear to what extent differences in outcomes reﬂect differences
in treatment choices, even if we follow standard risk adjustment
models, such as regression analysis or propensity score matching.
IV approach is a novel method to control for both observed
and unobserved differences between individuals. However, this
method is based on two strong assumptions and ignoring those
assumptions can result in severe bias and inefﬁciency of the
estimators.
A valid IV, which helps determine whether an individual is
treated but does not determine other factors that affect outcome
of interest, can overcome using the method of OLS. Current
literature clariﬁes how to interpret estimated treatment effects
using IVs. Because it is not possible to estimate the treatment
effect for each individual, researchers rely on average treatment
effect (ATE), which is the average of the individual treat-
ment effects across the whole population of interest. When the
treatment being evaluated has the same effect for everyone, any
valid instrument will identify the ATE. However, when responses
to treatment vary, different instruments measure different effects.
Under this more realistic assumption, the only effect we can be
Table 4 First stage estimation using probit regression
Variables
With IV-1 With IV-2 With IV-1 and IV-2
Coefﬁcient STD Coefﬁcient STD Coefﬁcient STD
Explanatory Variables
Age 0.01 0.00 0.01 0.00 0.0128 0.00
% Female 0.02 0.02 0.02 0.02 0.0205 0.02
Race
White 0.04 0.22 0.09 0.21 0.0663 0.22
Black -0.17 0.25 -0.13 0.24 -0.1547 0.25
Other -0.57 0.74 -0.53 0.74 -0.5517 0.74
Geographic Regions
Northeast -0.04 0.09 -0.04 0.09 -0.0377 0.09
North-Central -0.29 0.05 -0.28 0.05 -0.2753 0.05
West -0.20 0.08 -0.21 0.08 -0.2033 0.08
Year of Patient Identiﬁcation
1996 0.09 0.03 0.06 0.03 0.0645 0.03
1998 -0.02 0.03 0.00 0.03 -0.0047 0.03
1999 0.16 0.09 0.20 0.09 0.1898 0.09
Member Type
Employee 0.11 0.07 0.14 0.07 0.1367 0.07
Spouse 0.12 0.07 0.14 0.08 0.1426 0.08
Dependents
12–18 Years 0.05 0.05 0.06 0.05 0.0591 0.05
Others 0.10 0.06 0.11 0.06 0.1100 0.06
County Mean Household Income per $10,000 0.12 0.02 0.12 0.02 0.12 0.02
Number of Major Diagnosis Categories 0.03 0.01 0.03 0.01 0.0255 0.01
Charlson Comorbidity Index 0.16 0.01 0.16 0.01 0.1622 0.01
Asthma-Speciﬁc Comorbidities
Allergic Rhinitis 0.33 0.03 0.33 0.03 0.3320 0.03
Migraine 0.05 0.05 0.05 0.05 0.0507 0.05
Depression -0.08 0.04 -0.07 0.04 -0.0744 0.04
Gastrointestinal Disorder 0.00 0.03 0.00 0.03 -0.0017 0.03
Sinusitis 0.02 0.03 0.02 0.03 0.0180 0.03
Anxiety -0.06 0.07 -0.07 0.07 -0.0654 0.07
IVs
Controller/Reliever Copayment 0.08 0.06 N/A N/A 0.0286 0.07
Tax Provider ID controller % N/A N/A 0.72 0.33 0.6340 0.38
ID, identiﬁcation number; IV, instrumental variable; STD, standard deviation.
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sure the IV method estimates is the ATE among those who alter
their treatment status because they react to the instrument. This
is called local average treatment effect (LATE). When patients do
not make decisions to reach the instrument based on factors that
also determine treatment gains, the LATE equals the ATE among
those exposed to the treatment.
In our application, the consequence of instruments with little
explanatory power is increasing bias in the estimated IV coefﬁ-
cients and worsening the large sample approximations to the
ﬁnite sample distributions. With weak instruments, the large
sample bias of the IV estimator is the same as that of the OLS
estimator, and IV becomes inconsistent and nothing is gained
from instrumenting. One recommendation when faced with a
weak instrument is to be parsimonious in the choice of instru-
ments because if we use redundant instruments, even for the
cases where the identiﬁcation is not a problem, ﬁnal estimates are
inefﬁcient.
In the past, ingenious instruments have been proposed and
methods produced closer to “true” estimates than standard risk
adjustment models. In a recent article, Stukel compared four
analytic methods to remove the effects of selection bias in obser-
vational studies: multivariable model risk adjustment, propensity
score risk adjustment, propensity-based matching, and IV analy-
sis [56]. She concluded that the IV method produced closer
results to the results from RCTs, which balances both measurable
and immeasurable factors.
If we go back to our original question and answer: Do we
have a method to control for both observed and unobserved
bias? The answer is “theoretically YES” but practical application
is very limited because of the difﬁculty in ﬁnding the right instru-
ment. Researchers should test whether their instruments satisfy
the two key assumptions. Application of the instrument without
prior tests may produce inconsistent and inefﬁcient results, which
is worse than applying simple OLS or propensity score matching.
Therefore, the challenge for outcomes researchers remains to ﬁnd
and adopt the right instruments for outcomes research studies.
Otherwise, the cure can be worse than the disease.
The empirical work for this article was completed when the author
was an employee of Thomson-Reuters and presented at the ISPOR
conference.
Source of ﬁnancial support: None.
Table 5 Second stage estimation using generalized linear model with log link and gamma family
Variables
No IV With IV-1 With IV-2 With IV-1 and IV-2
Coefﬁcient STD Coefﬁcient STD Coefﬁcient STD Coefﬁcient STD
Explanatory Variables
Age 0.02 0.00 0.02 0.00 0.01 0.00 0.01 0.00
(%) Female -0.07 0.03 -0.06 0.03 -0.11 0.02 -0.11 0.02
Race
White -0.41 0.25 -0.40 0.25 -0.19 0.25 -0.18 0.25
Black -0.45 0.28 -0.46 0.28 -0.72 0.27 -0.72 0.27
Other -0.72 0.89 -0.75 0.89 -0.15 0.64 -0.16 0.64
Geographic Regions
Northeast 0.10 0.11 0.10 0.11 0.19 0.08 0.19 0.08
North-Central -0.12 0.05 -0.14 0.06 -0.25 0.05 -0.25 0.05
West -0.19 0.09 -0.20 0.09 -0.01 0.08 -0.02 0.08
Year of Patient Identiﬁcation
1996 -0.05 0.03 -0.05 0.03 -0.14 0.03 -0.14 0.03
1998 0.02 0.03 0.02 0.03 -0.09 0.03 -0.09 0.03
1999 0.05 0.10 0.06 0.11 -0.23 0.13 -0.23 0.13
Member Type
Employee 0.10 0.08 0.10 0.08 0.30 0.10 0.30 0.10
Spouse 0.14 0.08 0.14 0.08 0.43 0.11 0.43 0.11
Dependents
12–18 years 0.21 0.05 0.21 0.05 0.22 0.10 0.22 0.10
Others 0.37 0.07 0.37 0.07 0.96 0.10 0.96 0.10
County Mean Household Income per $10,000 -0.01 0.02 -0.01 0.03 0.06 0.02 0.06 0.02
Number of Major Diagnosis Categories 0.22 0.01 0.22 0.01 0.18 0.01 0.18 0.01
Charlson Comorbidity Index 0.12 0.01 0.13 0.02 0.12 0.01 0.12 0.01
Asthma-Speciﬁc Comorbidities
Allergic Rhinitis 0.04 0.03 0.07 0.04 -0.17 0.04 -0.17 0.04
Migraine 0.08 0.06 0.08 0.06 0.01 0.03 0.01 0.03
Depression 0.34 0.05 0.34 0.05 0.12 0.03 0.12 0.03
Gastrointestinal Disorder 0.17 0.03 0.17 0.03 0.19 0.03 0.19 0.03
Sinusitis 0.10 0.03 0.10 0.03 0.11 0.02 0.11 0.02
Anxiety 0.24 0.09 0.24 0.09 0.07 0.05 0.07 0.05
Treatment Indicator
Controller 0.11 0.03 0.12 0.29 0.38 0.28 0.25 0.30
First Stage Residual
Residual N/A N/A -0.18 0.12 -0.02 0.12 -0.12 0.11
Standard errors are adjusted for ﬁrst stage estimation.
IV, instrumental variable; STD, standard deviation.
Table 6 Comparison of differences in outcome measures between the
controller-only users and reliever-only users (standard errors are in
parentheses)
Cost Difference
Unadjusted $1,471 ($114)
OLS Estimate $260 ($75)
IV Estimate with Weak IV $270 ($613)
IV Estimate with Strong IV $894 ($611)
IV Estimate with Redundant IV $601 (618)
IV, instrumental variable; OLS, ordinary least squares.
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